The outcome of the CheckMate 040 study, in which nivolumab (anti-PD-1 antibody) was administered to patients with advanced HCC with or without chronic viral hepatitis has recently been published (173). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.